Balance Sheet

Accounts Payables Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Construction in Progress (2019 - 2020)

Legend Biotech filings provide 2 years of Construction in Progress readings, the most recent being $33.6 million for Q4 2020.

On a quarterly basis, Construction in Progress rose 1082.74% to $33.6 million in Q4 2020 year-over-year; TTM through Dec 2020 was $33.6 million, a 1082.74% increase, with the full-year FY2020 number at $33.6 million, up 1082.74% from a year prior.
Construction in Progress hit $33.6 million in Q4 2020 for Legend Biotech, up from $2.8 million in the prior quarter.
In the past five years, Construction in Progress ranged from a high of $33.6 million in Q4 2020 to a low of $2.8 million in Q4 2019.